Objective A hepatitis B immunogenic complex therapeutic vaccine , yeast-derived recombinant HBsAg combined with human anti-HBs immunoglobulin ( YIC ), was evaluated for safety and immune response in phase ⅰ clinical trial .
目的观察治疗性乙型肝炎(乙肝)疫苗(重组乙肝表面抗原和高效价抗乙肝免疫球蛋白组成的免疫复合物,简称乙肝疫苗)Ⅰ期临床研究中诱生的免疫应答作用。